$37.01
0.75% today
Nasdaq, Oct 31, 09:02 pm CET
ISIN
BMG5269C1010
Symbol
KNSA

Kiniksa Pharmaceuticals Ltd. Class A Stock price

$37.01
-1.82 4.69% 1M
+10.04 37.23% 6M
+17.23 87.11% YTD
+14.42 63.83% 1Y
+25.59 224.08% 3Y
+21.59 140.01% 5Y
+17.54 90.09% 10Y
+17.54 90.09% 20Y
Nasdaq, Closing price Fri, Oct 31 2025
-0.28 0.75%
ISIN
BMG5269C1010
Symbol
KNSA
Industry

Key metrics

Basic
Market capitalization
$2.8b
Enterprise Value
$2.5b
Net debt
positive
Cash
$307.8m
Shares outstanding
74.0m
Valuation (TTM | estimate)
P/E
621.5 | 86.2
P/S
5.3 | 4.9
EV/Sales
4.8 | 4.3
EV/FCF
37.9
P/B
5.7
Financial Health
Equity Ratio
75.5%
Return on Equity
-9.9%
ROCE
0.8%
ROIC
0.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$529.3m | $580.7m
EBITDA
$6.0m | $102.4m
EBIT
$4.5m | $40.4m
Net Income
$4.8m | $32.0m
Free Cash Flow
$66.5m
Growth (TTM | estimate)
Revenue
56.2% | 37.2%
EBITDA
123.5% | 333.2%
EBIT
116.3% | 188.5%
Net Income
146.8% | 174.1%
Free Cash Flow
119.4%
Margin (TTM | estimate)
Gross
85.9%
EBITDA
1.1% | 17.6%
EBIT
0.9%
Net
0.9% | 5.5%
Free Cash Flow
12.6%
More
EPS
$0.1
FCF per Share
$0.9
Short interest
6.4%
Employees
315
Rev per Employee
$1.3m
Show more

Is Kiniksa Pharmaceuticals Ltd. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Kiniksa Pharmaceuticals Ltd. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Kiniksa Pharmaceuticals Ltd. Class A forecast:

Buy
92%
Hold
8%

Financial data from Kiniksa Pharmaceuticals Ltd. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
529 529
56% 56%
100%
- Direct Costs 74 74
79% 79%
14%
455 455
53% 53%
86%
- Selling and Administrative Expenses 177 177
16% 16%
34%
- Research and Development Expense 99 99
14% 14%
19%
5.98 5.98
123% 123%
1%
- Depreciation and Amortization 1.50 1.50
26% 26%
0%
EBIT (Operating Income) EBIT 4.48 4.48
116% 116%
1%
Net Profit 4.79 4.79
147% 147%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Kiniksa Pharmaceuticals Ltd. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiniksa Pharmaceuticals Ltd. Class A Stock News

Positive
Seeking Alpha
one day ago
Kiniksa Pharmaceuticals leverages ARCALYST as it is a first-in-class FDA-approved treatment for recurrent pericarditis, driving recurring revenue and strong growth. Q3 FY2025 ARCALYST revenue was $180.9M (+61% YoY, +15% QoQ), prompting raised FY2025 guidance to $670–$675M. ARCALYST's efficacy and new ACC guidance support increased patient-months, leading to a more steady revenue stream and repo...
Neutral
Seeking Alpha
3 days ago
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jonathan Kirshenbaum - Investor Relations Officer Sanj Patel - CEO & Chairman of the Board Ross Moat - Executive VP & Chief Commercial Officer Mark Ragosa - Senior VP & CFO John Paolini - Executive VP & Chief Medical Officer Conference Call Participants Mary Kate Dav...
Neutral
GlobeNewsWire
3 days ago
– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET ...
More Kiniksa Pharmaceuticals Ltd. Class A News

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Sanj Patel
Employees 315
Founded 2015
Website www.kiniksa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today